Suppr超能文献

在实体器官移植中使用血管紧张素 II 型 1 型受体抗体——是否到了检测的时候？

Angiotensin II Type-1 Receptor Antibody in Solid Organ Transplantation - Is It Time to Test?

机构信息

Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, United Kingdom.

Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom.

出版信息

Transpl Int. 2024 Nov 13;37:13280. doi: 10.3389/ti.2024.13280. eCollection 2024.

DOI:10.3389/ti.2024.13280
PMID:39606688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11598415/
Abstract

Angiotensin II type-1 receptor antibody (AT1R-Ab) has been mooted as a potential effector of both acute and chronic antibody mediated rejection (AMR). A growing body of literature on the topic is now coming under scrutiny in the context of the evolving Banff AMR diagnostic classification system and refinement of recommendations for histocompatibility testing by the Sensitization in Transplantation Assessment of Risk (STAR) workgroup. This mini-review discusses the latest understanding of pathophysiological mechanisms, clinical evidence for the pathogenicity of AT1R-Ab, and methods of laboratory testing.

摘要

血管紧张素 II 型 1 型受体抗体（AT1R-Ab）一直被认为是急性和慢性抗体介导排斥反应（AMR）的潜在效应因子。目前，越来越多的关于该主题的文献正在接受审查，背景是不断发展的 Banff AMR 诊断分类系统和 Sensitization in Transplantation Assessment of Risk（STAR）工作组对组织相容性检测建议的细化。这篇迷你综述讨论了对病理生理机制的最新理解、AT1R-Ab 的致病性的临床证据以及实验室检测方法。

相似文献

1
Angiotensin II Type-1 Receptor Antibody in Solid Organ Transplantation - Is It Time to Test?
Transpl Int. 2024 Nov 13;37:13280. doi: 10.3389/ti.2024.13280. eCollection 2024.
2
Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications.
Transpl Int. 2024 Aug 12;37:13239. doi: 10.3389/ti.2024.13239. eCollection 2024.
3
Defining the Etiology of Renal Allograft Dysfunction Using Banff 2019 Classification: Correlation with Post-Transplant Duration and Creatinine Levels-A Comprehensive Analysis of 200 Renal Biopsies at a Tertiary Care Medical Center Hospital.
Int J Surg Pathol. 2024 Oct 3:10668969241283737. doi: 10.1177/10668969241283737.
4
Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients.
Cochrane Database Syst Rev. 2022 Sep 12;9(9):CD012854. doi: 10.1002/14651858.CD012854.pub2.
5
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Cochrane Database Syst Rev. 2017 Jan 11;1(1):CD004759. doi: 10.1002/14651858.CD004759.pub2.
6
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.
7
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Cochrane Database Syst Rev. 2017 Jul 20;7(7):CD004756. doi: 10.1002/14651858.CD004756.pub4.
8
Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
Transplantation. 2017 Mar;101(3):608-615. doi: 10.1097/TP.0000000000001231.
9
Immunosuppressive T-cell antibody induction for heart transplant recipients.
Cochrane Database Syst Rev. 2013 Dec 2;2013(12):CD008842. doi: 10.1002/14651858.CD008842.pub2.
10
Pre-transplant Screening for Non-HLA Antibodies: Who should be Tested?
Hum Immunol. 2018 Apr;79(4):195-202. doi: 10.1016/j.humimm.2018.02.001. Epub 2018 Feb 8.

本文引用的文献

1
Banff 2022 Liver Group Meeting report: Monitoring long-term allograft health.
Am J Transplant. 2024 Jun;24(6):905-917. doi: 10.1016/j.ajt.2024.03.008. Epub 2024 Mar 9.
2
Improved Graft Function following Desensitization of Anti-ATR and Autoantibodies in a Heart Transplant Recipient Negative for Donor-Specific Antibodies with Antibody-Mediated Rejection: A Case Report.
Int J Mol Sci. 2024 Feb 12;25(4):2218. doi: 10.3390/ijms25042218.
3
The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics.
Am J Transplant. 2024 Mar;24(3):338-349. doi: 10.1016/j.ajt.2023.10.016. Epub 2023 Oct 28.
4
Autoantibodies from patients with kidney allograft vasculopathy stimulate a proinflammatory switch in endothelial cells and monocytes mediated via GPCR-directed PAR1-TNF-α signaling.
Front Immunol. 2023 Oct 30;14:1289744. doi: 10.3389/fimmu.2023.1289744. eCollection 2023.
5
Report of the 2022 Banff Heart Concurrent: Focus on non-human leukocyte antigen antibodies in rejection and the pathology of "mixed" rejection.
Am J Transplant. 2024 Apr;24(4):533-541. doi: 10.1016/j.ajt.2023.10.004. Epub 2023 Oct 12.
6
Association of positive pre-transplant angiotensin II type 1 receptor antibodies with clinical outcomes in lung transplant recipients.
Transpl Immunol. 2023 Oct;80:101901. doi: 10.1016/j.trim.2023.101901. Epub 2023 Jul 11.
7
Association of MICA and AT1R antibodies with antibody-mediated rejection and cardiac allograft vasculopathy in a pediatric heart transplant recipient.
Transpl Immunol. 2023 Jun;78:101811. doi: 10.1016/j.trim.2023.101811. Epub 2023 Mar 6.
8
Sensitization in transplantation: Assessment of Risk 2022 Working Group Meeting Report.
Am J Transplant. 2023 Jan;23(1):133-149. doi: 10.1016/j.ajt.2022.11.009. Epub 2023 Jan 11.
9
Pre-transplant angiotensin II receptor type I antibodies in pediatric renal transplant recipients: An observational cohort study.
Pediatr Transplant. 2022 Dec;26(8):e14400. doi: 10.1111/petr.14400. Epub 2022 Sep 27.
10
Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
Transpl Immunol. 2022 Oct;74:101674. doi: 10.1016/j.trim.2022.101674. Epub 2022 Jul 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验